Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
TNB forms joint venture with Luminous Aspect, SME consortium for 500MW solar project

TNB forms joint venture with Luminous Aspect, SME consortium for 500MW solar project

BitgetBitget2026/11/03 09:19
  • Tenaga Nasional's subsidiary TNB Renewables signed a solar joint venture agreement with Luminous Aspect and CSP 500MW on November 3, 2026.
  • The project in Bahau, Negeri Sembilan, comprises 500MWac of solar capacity with a 250MW/1,000MWh battery energy storage system.
  • TNB Renewables holds 70% of the venture; IOI subsidiary Luminous Aspect owns 25%, with SME consortium CSP 500MW holding 5%.
  • The parent will inject up to RM 424.4 million through Ordinary Shares and Redeemable Preference Shares into TNB Renewables for the project.
  • Maximum equity capitalization is RM 606.2 million, with a planned debt-to-equity ratio of up to 80:20, subject to funding conditions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TNB - Tenaga Nasional Berhad published the original content used to generate this news brief via Bursa Malaysia (KLSE) (Ref. ID: 3721716) on November 03, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12